For this purpose, we treated immortalized myocytes derived from a healthy control (HC) or a DMD patient carrying a deletion of exons 48 through 50 with: a control ASO (not targeting DMD), an ASO targeting DMD exon 41 (generating an in-frame exon 41-skipped transcript in HC cells), or an ASO targeting DMD exon 51 (restoring the reading frame in these DMD cells); ASOs were tested alone as well as in combination with VPA treatment. This evidence concerns the gene DMD and Duchenne muscular dystrophy.